Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imaging.

Abstract

A new radiopharmaceutical, 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO) has shown considerable promise for single photon emission tomographic (SPECT) imaging of the brain. In animal biodistribution studies this complex demonstrates good brain uptake with prolonged retention of activity in brain. Further improvement of these properties, resulting in… (More)

Topics

Cite this paper

@article{Nowotnik1985DevelopmentOA, title={Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imaging.}, author={David P. Nowotnik and Lewis R. Canning and Sarah A Cumming and R. Chase Harrison and Binh Higley and G Nechvatal and Roger D. Pickett and Ian M. Piper and V J Bayne and Alan Forster}, journal={Nuclear medicine communications}, year={1985}, volume={6 9}, pages={499-506} }